Stock Events

Stock Events

Altimmune 

$3.42
319
+$0.19+5.88% Friday 20:00
+$0.02+0.58%Friday 23:48After hours

Statistics

Day High
3.43
Day Low
3.25
52W High
6.44
52W Low
2.56
Volume
4,849,066
Avg. Volume
4,443,177
Mkt Cap
665.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jan 17
$87.30
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.35
-0.27
-0.2
-0.12
Expected EPS
-0.135111
Actual EPS
N/A

Financials

-214,860.98%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
41,000Revenue
-88.09MNet Income

Analyst Ratings

13.67Average Price Target
The highest estimate is 20.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALT. It's not an investment recommendation.
Amazon
48
AMZN
NVIDIA
45
NVDA
Microsoft
39
MSFT
Apple
38
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.53B
Novavax is a direct competitor in the development of vaccines for infectious diseases, similar to Altimmune's focus area.
Moderna
MRNA
Mkt Cap55.09B
Moderna is involved in mRNA-based vaccines and therapeutics, competing in the same innovative vaccine technology space as Altimmune.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes with Altimmune in the development of vaccines, including their work on COVID-19 vaccines.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, through its partnership with BioNTech and other vaccine initiatives, is a major competitor in the vaccine market.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, with its global reach and vaccine development, competes in the same space as Altimmune.
Inovio Pharmaceuticals
INO
Mkt Cap133.38M
Inovio Pharmaceuticals is focused on DNA medicines, including vaccines, making it a competitor in the innovative vaccine development space.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline, with its extensive vaccine portfolio, is a significant competitor in the global vaccine market.
Sanofi
SNY
Mkt Cap107.39B
Sanofi is involved in vaccine development and distribution, making it a competitor in the global vaccine and immunotherapy market.

About

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Show more...
CEO
Jerome Benedict Durso
Employees
57
Country
United States
ISIN
US02155H2004
WKN
000A2N5Z6

Listings

STU
DE
3G0.STU
MU
DE
3G0.MU
MX
MX
ALT1.MX
LSE
GB
0A4C.LSE

0 Comments

Share your thoughts

FAQ

What is Altimmune stock price today?▼
The current price of ALT is $3.42 USD — it has increased by +5.88% in the past 24 hours. Watch Altimmune stock price performance more closely on the chart.
What is Altimmune stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Altimmune stocks are traded under the ticker ALT.
Is Altimmune stock price growing?▼
ALT stock has risen by +9.97% compared to the previous week, the month change is a +12.87% rise, over the last year Altimmune has showed a -9.52% decrease.
What is Altimmune market cap?▼
Today Altimmune has the market capitalization of 665.25M
When is the next Altimmune earnings date?▼
Altimmune is going to release the next earnings report on November 10, 2026.
What were Altimmune earnings last quarter?▼
ALT earnings for the last quarter are -0.12 USD per share, whereas the estimation was -0.14 USD resulting in a +11.44% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Altimmune revenue for the last year?▼
Altimmune revenue for the last year amounts to 41,000 USD.
What is Altimmune net income for the last year?▼
ALT net income for the last year is -88.09M USD.
Does Altimmune pay dividends?▼
Yes, ALT dividends are paid en. The last dividend per share was 87.3 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Altimmune have?▼
As of September 05, 2026, the company has 57 employees.
In which sector is Altimmune located?▼
Altimmune operates in the Health & Wellness sector.
When did Altimmune complete a stock split?▼
The last stock split for Altimmune was on September 14, 2018 with a ratio of 1:30.
Where is Altimmune headquartered?▼
Altimmune is headquartered in GAITHERSBURG, United States.